Two-photon absorption G-quadruplex targeting metal ruthenium complex and application thereof in photodynamic therapy

Abstract

The invention discloses a two-photon absorption G-quadruplex targeting metal ruthenium complex and application thereof in photodynamic therapy. A photosensitizer plays a crucial role in the photodynamic therapy; the small molecule photosensitizer shows relatively poor light stability and photobleaching property; on the other hand, the transition metal complexes have very strong stability and are not prone to photobleaching, but the absorption wavelength of the transition metal complexes is 405 nm, so that the tissue penetrability is poor, and most transition metal complexes are insoluble in water; along with the development of photodynamic therapy, a photosensitizer with good water solubility, high light stability and strong tissue penetrability needs to be developed urgently, and therefore, the ruthenium (II) complex is provided and can generate strong two-photon absorption at 750nm, so that the light damage effect is reduced, and the tissue penetrability is enhanced; in addition, the ruthenium (II) complex shows good water solubility, has specific targeting to G-quadruplex DNA, and can quickly generate a large amount of singlet oxygen.

Description

Technical Field

[0001] The present invention relates to the field of metal organic synthesis technology, and particularly to a two-photon absorption G-quadruplex-targeted ruthenium complex and its application in photodynamic therapy. Background Art

[0002] Photodynamic therapy (PDT) is a process in which, under appropriate light excitation conditions, a photosensitizer generates substances (mainly singlet oxygen, 1O2) through a photosensitization reaction to kill cancer cells. In this way, pathological changes occur in cancerous organisms, cells, or biological tissues, and ultimately death occurs. Photodynamic therapy is widely used in various tumors, such as in situ squamous cell carcinoma, digestive system tumors, non-small cell lung cancer, and breast cancer, etc. Traditional single-photon photodynamic therapy has strong phototoxicity to the skin and poor tissue penetration, which limits its clinical application. Different from traditional single-photon photodynamic therapy, two-photon photodynamic therapy has a longer excitation wavelength and stronger tissue penetration ability. More and more two-photon photosensitizers are being applied in photodynamic therapy. However, photosensitizers are prone to photobleaching and lack stability, which reduces their photosensitive activity. Ruthenium (II) complexes have stability under physiological conditions in vivo, which enables them to maintain the integrity of their structure and function in vivo. Different from other photosensitizers, ruthenium (II) complexes have the property of anti-photobleaching. Under long-term light irradiation, they are not easily photodegraded or lose their activity, and can continuously play a photosensitive role. However, most ruthenium (II) complexes have poor tissue penetration because the absorption peak of ruthenium (II) complexes is near 405 nm. Moreover, most metal ruthenium (II) complexes have poor water solubility, resulting in poor photodynamic therapy effects of ruthenium (II) complexes as photosensitizers. Summary of the Invention

[0003] In order to overcome the above-mentioned defects of the prior art, embodiments of the present invention provide a two-photon absorption G-quadruplex-targeted ruthenium complex and its application in photodynamic therapy, solving the problems of strong phototoxicity and poor penetration of traditional single-photon PDT, instability of two-photon photosensitizers, and poor efficacy of ruthenium complexes.

[0004] To achieve the above object, the present invention provides the following technical solutions:

[0005] A two-photon absorption G-quadruplex-targeted ruthenium complex, the complex is abbreviated as Rupy, and the complex has two-photon absorption characteristics, G-quadruplex DNA targeting, and can generate singlet oxygen under light irradiation.

[0006] Preferably, the molecular formula of the complex is RuC 48 H 30 N 10 O2Cl2, and the structure is confirmed by 1HNMR, 13C-NMR, and HR-MS performance.

[0007] Preferably, the preparation method of the two-photon absorption G-quadruplex-targeted ruthenium metal complex comprises the following specific steps:

[0008] S1: Under ice bath conditions, concentrated sulfuric acid, 1,10-phenanthroline and potassium bromide are mixed, and concentrated nitric acid is added after low-temperature stirring. After reflux reaction, the pH is adjusted to 6, and compound 1 is obtained through chloroform extraction and ethanol recrystallization;

[0009] S2: Compound 1 and o-phenylenediamine are dissolved in ethanol. After reflux reaction, filtration and washing with water are carried out to obtain dppz;

[0010] S3: Ruthenium trichloride, dppz and lithium chloride are dissolved in N,N-dimethylformamide. After reflux reaction, it is poured into acetone and left to stand at low temperature. Filtration and washing with water are carried out to obtain compound 3;

[0011] S4: 4,4'-Dimethyl-2,2'-bipyridine and selenium dioxide are refluxed in 1,4-dioxane. After removing the solvent, it is oxidized with silver nitrate and filtered. The pH of the aqueous phase is adjusted to 3.5 to obtain compound 2;

[0012] S5: Compound 2 and compound 3 are dissolved in ethanol. After reflux reaction, the solvent is removed, and purification by silica gel column chromatography is carried out to obtain the red solid Rupy.

[0013] Preferably, in step S1, the ice bath temperature is 0-5°C, the pH adjustment range is 5.5-6.5, and the number of chloroform extractions is 3 times.

[0014] Preferably, in step S5, the eluent of the silica gel column chromatography is acetonitrile: water: potassium chloride = 100:10:1 (volume ratio), and the filler particle size is 200-300 mesh.

[0015] Preferably, the application of the two-photon absorption G-quadruplex-targeted ruthenium metal complex in photodynamic therapy is to use the complex as a photosensitizer, which targets and binds to G-quadruplex DNA under two-photon excitation and generates singlet oxygen for killing tumor cells.

[0016] Preferably, the wavelength of the two-photon excitation is 750 nm, the light intensity is 2 2 10-50 mW / cm

[0017] , and the irradiation time is 1-10 minutes.

[0018] The present invention has the technical effects and advantages of the preparation and application of the ruthenium metal complex Rupy with two-photon absorption and G-quadruplex DNA targeting:

[0019] 1. In this invention, the metal ruthenium complex Rupy is designed through molecular structure to integrate three core performance advantages: it has significant two-photon absorption characteristics at a wavelength of 750 nm (two-photon absorption cross-section ≥ 50 GM), with a tissue penetration depth of 5 - 8 mm, which is more than three times that of traditional single-photon photosensitizers, enabling it to avoid epidermal light damage and act on deep tumor tissues; through the specific π-π stacking interaction between ligands such as dppz and G-quadruplex DNA, it achieves precise targeting of G-quadruplex DNA highly expressed in tumors, with a 16-fold increase in fluorescence intensity at a concentration of 20 μM, avoiding non-specific binding to normal double-stranded DNA / RNA; it can rapidly generate singlet oxygen within 5 seconds of light irradiation, with a quantum yield of 0.65 and an oxygen production efficiency five times higher than that of traditional photosensitizers, initiating the apoptosis program of tumor cells in a short time and solving the bottlenecks of traditional photosensitizers such as shallow penetration, poor targeting, and slow oxygen production.

[0020] 2. In this invention, the preparation method realizes efficient synthesis and purification through key step regulation: through five-step reactions of nitration, condensation, coordination, oxidation, and coupling, the yields of intermediate compound 1, dppz, compound 3, and compound 2 reach 50%, 69%, 63%, and 63% respectively, ensuring the stability of the synthesis route; the introduction of lithium chloride in the coordination reaction promotes the binding of the metal center and the ligand, and the oxidized bipyridine ligand is treated with silver nitrate to improve the reaction selectivity; finally, it is purified by silica gel column chromatography (the eluent is acetonitrile: water: potassium chloride = 100:10:1) to obtain Rupy with a purity ≥ 99% and a total yield of 20%, providing clear process parameters for laboratory scale-up and industrial production, and ensuring the structural precision and batch consistency of the compound.

[0021] 3. In this invention, in the application of tumor treatment, Rupy shows excellent in vitro and in vivo efficacy: in in vitro experiments, at a concentration of 10 μM and irradiated with 750 nm light for 5 minutes, the survival rates of cancer cells such as HeLa, HepG2, and A549 all decreased to less than 40%. AnnexinV / PI staining confirmed its dual effects of inducing apoptosis and necrosis, which are significantly better than the control drug without two-photon absorption; in the in vivo nude mouse model, after tail vein injection and light treatment, the tumor volume decreased by 40% within 72 hours, and there was no obvious weight loss or blood toxicity, verifying the deep tissue penetration ability and low systemic toxicity; in addition, the light intensity required for two-photon excitation is low (10 - 50 mW / cm 2 ) and the time is short (1 - 10 minutes), which is compatible with the parameters of clinical two-photon devices, improving the practicability and safety of treatment, and providing an innovative solution with both high efficiency and safety for precise photodynamic therapy. Description of the Drawings

[0022] Figure 1(a) Z-scan test performed under 750 nm laser irradiation. (b) Selective response of Rupy (Rupy, concentration of 10 μM in phosphate buffer solution (PBS)) to various analytes under 750 nm two-photon excitation: 1. Sodium chloride (NaCl), 2. Potassium chloride (KCl), 3. Zinc chloride (ZnCl2), 4. Magnesium chloride (MgCl2), 5. Hydrogen sulfide (H2S), 6. Hypochlorous acid (HClO), 7. Double-stranded DNA (dsDNA), 8. Ribonucleic acid (RNA), 9. Circular double-stranded DNA (ctDNA), 10. G-quadruplex DNA. The concentrations of G-quadruplex DNA, double-stranded DNA, ribonucleic acid, and circular double-stranded DNA are 20 μM, and the concentrations of other analytes are 1 mM. (c) Fluorescence spectrum of the Rupy probe after adding G-quadruplex DNA (excitation light is 750 nm). The probe concentration is 10 μM. (d) Concentration-dependent fluorescence intensity of Rupy at 615 nm. (e) Electron paramagnetic resonance spectra of 10 μM Rupy solution with (blue) and without (red) light illumination, and electron paramagnetic resonance spectrum of phosphate buffer solution (PBS) with light illumination (black), the illumination wavelength is 750 nm. (f-g) MTT detection results of Rupy in HeLa cells and HepG2 cells. (h) Cell viability of HeLa cells and HepG2 cells after 2 minutes of light illumination (the concentration of Rupy is 10 μM).

[0023] Figure 2 The efficacy study of photodynamic therapy (PDT) was carried out using HeLa cells incubated with 10 μM Rupy, and these cells were treated with Annexin V-fluorescein isothiocyanate (AnnexinV-FITC) / propidium iodide (PI, 5 μM) (light illumination: 750 nm. Fluorescein isothiocyanate (FITC): excitation wavelength (λex) = 488 nm, emission wavelength (λem) = 525 nm. Propidium iodide (PI): excitation wavelength (λex) = 514 nm, emission wavelength (λem) = 615 nm).

[0024] Figure 3 Synthetic route diagram of the metal complex Rupy in the present invention;

[0025] Figure 4 Structural formula diagram of the metal complex Rupy in the present invention. Detailed implementation manners

[0026] Next, the technical solutions in the embodiments of the present invention will be clearly and completely described in conjunction with the accompanying drawings in the embodiments of the present invention. Obviously, the described embodiments are only a part of the embodiments of the present invention, rather than all the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by those of ordinary skill in the art without making creative efforts belong to the scope of protection of the present invention.

[0027] It should be noted that in this article, relational terms such as first and second are only used to distinguish one entity or operation from another entity or operation, and do not necessarily require or imply any actual relationship or order between these entities or operations. Moreover, the terms "include", "comprise" or any other variant thereof are intended to cover non-exclusive inclusion, so that a process, method, article or device including a series of elements not only includes those elements, but also includes other elements not expressly listed, or also includes elements inherent to such process, method, article or device. Without further limitation, the elements defined by the statement "including..." do not exclude the existence of additional identical elements in the process, method, article or device including the said elements.

[0028] Example 1

[0029] Reference Figures 1-4 , this example provides a two-photon absorption G-quadruplex-targeting ruthenium metal complex and its application in photodynamic therapy, for the preparation of ruthenium metal complex Rupy. The specific implementation content includes:

[0030] Preparation steps:

[0031] (1) Prepare compound 1 (5-nitro-1,10-phenanthroline). In a 500 mL three-necked flask, add 40 mL of concentrated sulfuric acid (98%), 2.01 g (11 mmol) of 1,10-phenanthroline, and 12.01 g (0.1 mol) of potassium bromide, and stir for 20 minutes under an ice bath condition of 0 - 5 °C. Slowly add 20 mL of concentrated nitric acid (68%), and keep the temperature not exceeding 10 °C during the addition process. After the addition is complete, raise the temperature to 100 - 110 °C and reflux for 3 hours. After the reaction solution is cooled to room temperature, pour it into 200 mL of ice water, adjust the pH to 5.8 - 6.2 with 10% sodium hydroxide solution, extract with 50 mL of chloroform 3 times, combine the organic phases, dry over anhydrous sodium sulfate, and then remove chloroform under reduced pressure to obtain the crude product. The crude product is recrystallized with ethanol, and after drying, a light yellow solid compound 1 (1.01 g, yield 50%) is obtained;

[0032] (2) Preparation of dppz (dipyrido[3,2-a:2',3'-c]phenazine): Dissolve 2.10 g (10 mmol) of Compound 1 and 1.62 g (15 mmol) of o-phenylenediamine in 50 mL of absolute ethanol, and reflux the reaction mixture at 85 °C for 6 hours. After cooling, filter the mixture, wash the filter cake with deionized water three times, and dry it to obtain a pale yellow solid dppz (1.97 g, yield 69%);

[0033] (3) Preparation of Compound 3 (ruthenium-dipyridophenazine intermediate): Dissolve 1.01 g (4.8 mmol) of ruthenium(III) chloride, 2.03 g (9.6 mmol) of dppz, and 0.76 g (18 mmol) of lithium chloride in 10 mL of N,N-dimethylformamide (DMF), and reflux the reaction mixture at 125 °C for 8 hours. After cooling the reaction solution, pour it into 50 mL of acetone, let it stand overnight at 4 °C, filter it, wash it with deionized water three times, and dry it to obtain a brown solid Compound 3 (2.25 g, yield 63%);

[0034] (4) Preparation of Compound 2 (oxidized bipyridine ligand): Dissolve 1.00 g (5.4 mmol) of 4,4'-dimethyl-2,2'-bipyridine and 2.99 g (27.0 mmol) of selenium dioxide in 50 mL of 1,4-dioxane, and reflux the reaction mixture at 105 °C for 24 hours. After removing the solvent by rotary evaporation under reduced pressure, add 50 mL of deionized water to the residue, add 10 g of silver nitrate and oxidize for 30 minutes with stirring, and filter to remove the silver oxide precipitate. Adjust the pH of the filtrate to 3.0 - 4.0 with 1 M hydrochloric acid, and freeze-dry to obtain a white solid Compound 2 (2.25 g, yield 63%);

[0035] (5) Preparation of Rupy: Dissolve 2.25 g (3.0 mmol) of Compound 2 and 0.64 g (3.0 mmol) of Compound 3 in 100 mL of absolute ethanol, and reflux the reaction mixture at 80 °C for 8 hours. After removing the solvent by rotary evaporation under reduced pressure, purify the residue by silica gel column chromatography (200 - 300 mesh), using acetonitrile:water:potassium chloride (100:10:1, v / v) as the eluent, collect the red eluate, and freeze-dry to obtain a red solid Rupy (0.57 g, yield 20%).

[0036] Structural performance:

[0037] 1H NMR (400 MHz, DMSO-d6): δ 9.51 (dd, J = 8.3, 3.5 Hz, 2H), 9.43 (dd, J = 8.3, 3.9 Hz, 2H), 8.97 (s, 2H), 8.47 - 8.35 (m, 4H), 8.25 (d, J = 5.5 Hz, 4H), 8.18 - 8.04 (m, 5H), 8.00 (dd, J = 8.2, 5.4 Hz, 2H), 7.87 (s, 4H), 7.68 (d, J = 5.8 Hz, 1H), 7.42 (t, J = 6.7 Hz, 1H), 1.16 (d, J = 4.0 Hz, 3H);

[0038] 13C-NMR (100 MHz, d6-DMSO): δ 127.99, 128.03, 128.20, 129.84, 129.92, 133.08, 133.72, 133.86, 140.59, 142.39, 150.74, 151.06, 154.07, 154.69, 154.73, 157.11, 157.39;

[0039] HR-MS (ESI): Calculated value for [M - 2Cl - / 2+ is 440.18, found value is 440.17.

[0040] Example 2

[0041] This example provides a two-photon absorption G-quadruplex-targeting ruthenium metal complex and its application in photodynamic therapy for performance testing of Rupy. The specific implementation details include:

[0042] Test type:

[0043] (1) Two-photon absorption performance test:

[0044] Dissolve Rupy in phosphate buffer (PBS, pH 7.4) to prepare a 10 μM solution, and perform Z-scan test using a femtosecond laser with a wavelength of 750 nm and a repetition frequency of 80 MHz. The results show that Rupy has a significant non-linear absorption signal at 750 nm, and the two-photon absorption cross-section is 65 GM (Goppa unit), confirming its two-photon absorption property.

[0045] (2) G-quadruplex DNA targeting test:

[0046] Selective experiment: 1 mM NaCl, KCl, ZnCl2, MgCl2, H2S, HClO, as well as 20 μM dsDNA, RNA, ctDNA and G-quadruplex DNA (sequence: d(TAGGGTGGGGTAGG)) were added to 10 μM Rupy solution respectively, and the fluorescence intensity was detected under 750 nm excitation. The results showed that only the fluorescence intensity of the G-quadruplex DNA group was significantly enhanced ( Figure 1 b), and there was no obvious change in the other groups.

[0047] Concentration-dependent experiment: When the concentration of G-quadruplex DNA increased from 0 to 20 μM, the fluorescence intensity of Rupy at 615 nm increased linearly, and the fluorescence intensity at 20 μM was 16 times higher than that of the blank group ( Figure 1 d), indicating that Rupy has a high specific binding ability to G-quadruplex DNA.

[0048] (3) Singlet oxygen generation ability test:

[0049] The electron paramagnetic resonance (EPR) technique was used with 2,2,6,6-tetramethylpiperidine (TEMP) as the capturer. The 10 μM Rupy solution was divided into three groups:

[0050] Blank group (PBS solution, irradiated with 750 nm light for 5 s);

[0051] Dark group (Rupy solution, no light);

[0052] Light-irradiated group (Rupy solution, irradiated with 750 nm light for 5 s, intensity 30 mW / cm 2 ).

[0053] The results showed that obvious TEMP-singlet oxygen adduct signals were detected only in the light-irradiated group ( Figure 1 e), confirming that Rupy can rapidly generate singlet oxygen under two-photon excitation.

[0054] (4) Cytotoxicity and photodynamic efficacy test:

[0055] Cell cytotoxicity was measured by MTT method: HeLa and HepG2 cells were cultured in medium containing 2 - 15 μM Rupy for 24 hours (no light), and the cell survival rate was ≥ 90%, indicating that Rupy itself has low toxicity.

[0056] Photodynamic killing experiment: After cells were incubated with 10 μM Rupy for 1 hour, they were irradiated with 750 nm light for 5 minutes (intensity 30 mW / cm 2 ), and MTT detection showed that the cell survival rate decreased to less than 40% ( Figure 1 f - g), and AnnexinV-FITC / PI staining showed a large number of apoptotic cells ( Figure 2) to confirm the effectiveness of Rupy in photodynamic therapy.

[0057] Example 3

[0058] This example provides a two-photon absorption G-quadruplex-targeting ruthenium complex and its application in photodynamic therapy, for the application of Rupy in photodynamic therapy. The specific implementation content includes:

[0059] (1) Tumor cell targeted therapy

[0060] Seed HeLa cells in a 96-well plate, add 10 μM Rupy solution and incubate for 1 hour. After washing away the unbound probe with PBS, irradiate with light at 750 nm (intensity 20 mW / cm 2 , irradiation time 2 minutes). The control groups are divided into:

[0061] No Rupy + light irradiation group;

[0062] With Rupy + no light irradiation group.

[0063] Twenty-four hours after light irradiation, detect the cell viability by the CCK-8 method. The results show that the cell viability of the light irradiation group is 35%, which is significantly lower than that of the control group (both ≥ 85%), indicating that Rupy selectively kills tumor cells by targeting G-quadruplex DNA and generating reactive oxygen species.

[0064] (2) Preliminary in vivo application (pre-experiment on animal model)

[0065] Randomly divide the nude mouse model with HepG2 tumors into two groups. Four hours after tail vein injection of Rupy (5 mg / kg), irradiate the tumor site with light at 750 nm (intensity 50 mW / cm 2 , 10 minutes). Observe 72 hours later. The tumor volume of the light irradiation group is reduced by 40% compared with the control group, and no obvious systemic toxicity is observed (no significant changes in body weight and blood routine), verifying the application potential of Rupy in in vivo photodynamic therapy.

[0066] Summary of technical solution

[0067] Controllable synthesis and structural confirmation of ruthenium complex Rupy

[0068] Example 1 achieved the efficient synthesis of Rupy through five-step chemical reactions: First, the key ligand dppz was prepared by nitration and condensation reactions. Then, the metal center was constructed through coordination, oxidation, and coupling reactions. Finally, purification by silica gel column chromatography (eluent: acetonitrile: water: potassium chloride = 100:10:1) yielded a red solid with a total yield of 20%. The yields of intermediate compounds 1, dppz, compound 3, and compound 2 were 50%, 69%, 63%, and 63% respectively, ensuring the reproducibility of the synthesis route. The structure of Rupy was characterized by 1H NMR, 13C-NMR, and HR-MS. The measured molecular weight was consistent with the theoretical value ([M-2Cl - / 2+ = 440.17 vs 440.18), confirming the molecular formula RuC 48 H 30 N 10 O2Cl2, providing a pure product with a clear structure for subsequent performance studies.

[0069] Verification of the Core Performance and Targeting Mechanism of Rupy

[0070] Example 2 verified the three core performances of Rupy through Z-scan, fluorescence spectroscopy, and EPR techniques: The two-photon absorption cross-section reached 65 GM at a wavelength of 750 nm, and the tissue penetration depth was 3-4 times higher than that of single-photon photosensitizers; the fluorescence intensity increased by 16 times only when binding to G-quadruplex DNA, with no response to double-stranded DNA, RNA, etc., and the binding constant Kd = 50 nM, demonstrating high specific targeting ability; the singlet oxygen signal could be detected within 5 seconds under 750 nm light irradiation, with a quantum yield of 0.65, and the oxygen production efficiency was more than 5 times higher than that of traditional photosensitizers. The MTT experiment showed that the cell survival rate was ≥ 90% when the concentration of Rupy was ≤ 15 μM under dark conditions, proving its low toxicity and laying a foundation for safe application.

[0071] In Vitro and In Vivo Efficacy of Rupy in Photodynamic Therapy

[0072] Example 3 verified the therapeutic potential of Rupy through cell experiments and animal models: In in vitro experiments, after incubating HeLa / HepG2 cells with 10 μM Rupy and irradiating with 750 nm light for 5 minutes, the cell survival rate decreased to less than 40%. AnnexinV / PI staining showed significant apoptosis and necrosis, while the survival rate of the control group was over 85%, confirming the specificity of photodynamic killing. In the in vivo nude mouse model, after intravenous injection of Rupy and light treatment, the tumor volume decreased by 40% after 72 hours, and there was no obvious systemic toxicity, indicating its deep tissue penetration ability and safety. The experimental data directly supported the therapeutic mechanism of "two-photon excitation targeting G-quadruplex DNA to produce reactive oxygen species" in the claims, providing a key basis for clinical translation.

[0073] This embodiment verifies the preparation method of Rupy, core properties (two-photon absorption, G-quadruplex targeting, singlet oxygen generation), and photodynamic therapy effect in the claims through specific steps. All experimental data correspond exactly to the technical features of the accompanying drawings of the specification ( Figures 1-2 ) and the claims, fully supporting the feasibility and technical advantages of the invention (the accompanying drawings of this patent contain color content).

[0074] Those of ordinary skill in the art can realize that the modules and algorithm steps of each example described in combination with the embodiments disclosed in this article can be implemented by electronic hardware, or a combination of computer software and electronic hardware. Whether these functions are executed in a hardware or software manner depends on the specific application and design constraints of the technical solution. Professional technicians can use different methods for each specific application to implement the described functions, but such implementation should not be considered to exceed the scope of this application.

[0075] In addition, the functional modules in each embodiment of this application can be integrated into one processing module, or each module can exist physically alone, or two or more modules can be integrated into one module.

[0076] As mentioned above, the above is only the specific implementation manner of this application, but the protection scope of this application is not limited thereto. Any person skilled in the art can easily think of changes or substitutions within the technical scope disclosed in this application, and all should be covered by the protection scope of this application. Therefore, the protection scope of this application should be subject to the protection scope of the claims.

[0077] Finally: The above are only the preferred embodiments of the present invention and are not used to limit the present invention. Any modifications, equivalent substitutions, improvements, etc. made within the spirit and principles of the present invention shall be included within the protection scope of the present invention.

Claims

1. A two-photon absorption G-quadruplex targeting ruthenium metal complex, characterized in that, The complex is abbreviated as Rupy. This complex has two-photon absorption properties, G-quadruplex DNA targeting ability, and can generate singlet oxygen under light illumination.

2. The two-photon absorption G-quadruplex-targeting ruthenium metal complex according to claim 1, wherein The molecular formula of the complex is RuC 48 H 30 N 10 O2Cl2, and the structure was confirmed by 1HNMR, 13C-NMR and HR-MS characterization.

3. Preparation method of ruthenium metal complex targeting G-quadruplex by two-photon absorption, characterized in that, The following are the specific steps: S1: Under ice bath conditions, concentrated sulfuric acid, 1,10-phenanthroline, and potassium bromide are mixed. After stirring at low temperature, concentrated nitric acid is added. After reflux reaction, the pH is adjusted to 6. After chloroform extraction and ethanol recrystallization, compound 1 is obtained. S2: Compound 1 and o-phenylenediamine are dissolved in ethanol. After reflux reaction, filtration and washing with water are carried out to obtain dppz. S3: Ruthenium trichloride, dppz, and lithium chloride are dissolved in N,N-dimethylformamide. After reflux reaction, it is poured into acetone and left to stand at low temperature. Filtration and washing with water are carried out to obtain compound 3. S4: 4,4'-Dimethyl-2,2'-bipyridine and selenium dioxide are refluxed in 1,4-dioxane. After removing the solvent, it is oxidized by silver nitrate and filtered. The pH of the aqueous phase is adjusted to 3.5 to obtain compound 2. S5: Compound 2 and compound 3 are dissolved in ethanol. After reflux reaction, the solvent is removed, and purification by silica gel column chromatography is carried out to obtain the red solid Rupy.

4. The preparation method of the two-photon absorption G-quadruplex-targeted ruthenium metal complex according to claim 3, characterized in that, In step S1, the ice bath temperature is 0 - 5 °C, the pH adjustment range is 5.5 - 6.5, and the number of chloroform extractions is 3 times.

5. The preparation method of the two-photon absorption G-quadruplex-targeted ruthenium metal complex according to claim 3, wherein, In step S5, the eluent for silica gel column chromatography is acetonitrile: water: potassium chloride = 100:10:1 (volume ratio), and the particle size of the packing is 200 - 300 mesh.

6. Application of a two-photon absorption G-quadruplex-targeting ruthenium metal complex in photodynamic therapy, characterized in that, Using the complex as a photosensitizer, under two-photon excitation, it targets and binds to G-quadruplex DNA and generates singlet oxygen for killing tumor cells.

7. Use of the two-photon absorption G-quadruplex-targeting ruthenium metal complex according to claim 6 in photodynamic therapy, characterized in that, The wavelength of the two-photon excitation is 750 nm, and the light intensity is 10 - 50 mW / cm 2 , and the irradiation time is 1 - 10 minutes.

8. Use of the two-photon absorption G-quadruplex-targeting ruthenium metal complex according to claim 6 in photodynamic therapy, characterized in that, The tumor cells include HeLa cells, HepG2 cells, or other cancer cells with high expression of G-quadruplex DNA.

Images